Detail akcie ImmunityBio Rg online

Business Summary: Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Immunitybio Inc revenues increased from $7.2M to $75M. Net loss decreased 18% to $289.5M. Revenues reflect Product revenues increase from $6.9M to $74.7M, Other revenues increase of 18% to $293K. Lower net loss reflects Selling, General and Administrative decrease of 19% to $89.1M (expense), Interest expense - Balancing value decrease of 22% to $46M (expense).